Chung, Jon H.

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 741

Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers

Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 348

Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA

Clark, T. A., Chung, J. H., Kennedy, M., Hughes, J. D., Chennagiri, N., Lieber, D. S., Fendler, B., Young, L., Zhao, M., Coyne, M., et al. (2018) · The Journal of Molecular Diagnostics

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 200

Cdk2 is required for p53-independent G2/M checkpoint control

Chung, J. H., & Bunz, F. (2010) · PLoS Genetics

Cancer-related Molecular PathwaysDNA Repair Mechanisms

Cited by 105

An Open-Label Randomized Phase 2 Study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

Necchi, A., Giannatempo, P., Raggi, D., Mariani, L., Colecchia, M., Farè, E., Monopoli, F., Calareso, G., Ali, S. M., Ross, J. S., et al. (2019) · European Urology

Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers

Cited by 78